Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, is excited about the new Eliminate Hepatitis C (HCV) program put forth by the Biden Administration and being led by former NIH Director Francis Collins, MD, PhD, who is serving as a scientific advisor to the Biden Administration. “This is something we have been asking for years…We know we can end hepatitis C,” Schmid stated.
Carl Schmid discusses discrimination in prescription drug formularies, demonstrating how some PBMs and private insurers violate ACA provisions and hurt patients by placing life-saving prescription drugs on higher cost tiers.
Carl Schmid, along w/ other NAIC consumer reps., provides federal update at its Fall Meeting in Tampa with a focus on updated regulations to strengthen ACA Section 1557 non-discrimination rule and copay accumulator litigation to ensure copay assistance counts.
Carl Schmid describes the steps that can be taken to reduce inequities in PrEP uptake, focusing on community and provider education in episode 14 of Managed Healthcare Executive’s “Evaluating the Current and Future Opportunities for HIV PrEP.”
![[VIDEO] From platform to policy: 2021 Healthcare Agenda](https://hivhep.org/wp-content/uploads/2020/12/The-Hill-Health-Panel-1-1080x675.jpg)
Looks at the future of healthcare under the Biden administration and the 117th Congress, featuring discussion with Carl Schmid, Senator Bill Cassidy, Lauren Underwood, and healthcare officials.